Literature DB >> 30521789

Comparison of electroencephalogram (EEG) response to MDPV versus the hallucinogenic drugs MK-801 and ketamine in rats.

Ibrahim M Shokry1, Vikash Sinha2, Guilherme Da Silva2, Sol-Be Park2, John J Callanan3, Rui Tao4.   

Abstract

Synthetic cathinones, often marketed as 'bath salts', have been reported to induce an excited delirium syndrome with characteristic symptoms such as paranoid, hallucination and even aggression. 3,4-Methylenedioxypyrovalerone (MDPV), a norepinephrine-dopamine reuptake inhibitor (NDRI), is one of the psychoactive ingredients in bath salts. The present study utilized cortical EEG and brain microdialysis in rats to compare the effects of MDPV (0.25, 1 and 2 mg/kg, i.p.) with the hallucinogenic drugs MK-801 (0.05, 0.1 and 0.5 mg/kg, i.p.) and ketamine (5, 15 and 25 mg/kg, i.p.). Results revealed that MDPV similar to MK-801 and ketamine caused a dose-dependent increase in the cortical EEG synchronization. In addition, all three drugs produced an increase in DA efflux in the prefrontal cortex (FCx). However, there existed difference between the three drugs. In contrast to MDPV, MK-801 and ketamine had only moderate or little effects on DA efflux in the nucleus accumbens (NAcc). Except for ketamine, the effects of MDPV and MK-801 on EEG synchronization were blocked by the D1 receptor antagonist SCH23990 (0.1 mg/kg, i.p.) and D2 receptor antagonist sulpiride (100 mg/kg, i.p.). SCH23990 or sulpiride had no effect on ketamine-induced increases in EEG synchronization. In summary, the present comparative studies suggest that DA in the FCx, but unlikely the NAcc, exerts a critical role in increasing EEG synchronization associated with the excited delirium syndrome. Neural circuits consisting of glutamatergic and GABAergic neurons responsible for the hallucinogenic effect are discussed in the context of hyperdopamine and dysconnection theories for hallucinatory behaviors. Published by Elsevier Inc.

Entities:  

Keywords:  Bath salts; Dopamine; EEG synchronization; Hallucination; MDPV

Mesh:

Substances:

Year:  2018        PMID: 30521789     DOI: 10.1016/j.expneurol.2018.12.001

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

1.  Neurotoxicological Profiling of Paraquat in Zebrafish Model.

Authors:  Seong Soon Kim; Kyu-Seok Hwang; Hyemin Kan; Jung Yoon Yang; Yuji Son; Dae-Seop Shin; Byung Hoi Lee; Chong Hak Chae; Myung Ae Bae
Journal:  Neurochem Res       Date:  2022-05-13       Impact factor: 4.414

2.  Exploration of the cortical pathophysiology underlying visual disturbances in schizophrenia comorbid with depressive disorder-An evidence from mouse model.

Authors:  Jian Liu; Lidan Zheng; Tao Fang; Ranli Li; Xiaoyan Ma; Yun Sun; Lina Wang; Hongjun Tian; Deguo Jiang; Chuanjun Zhuo
Journal:  Brain Behav       Date:  2021-03-17       Impact factor: 2.708

Review 3.  Microdialysis and microperfusion electrodes in neurologic disease monitoring.

Authors:  Luke A Stangler; Abbas Kouzani; Kevin E Bennet; Ludovic Dumee; Michael Berk; Gregory A Worrell; Steven Steele; Terence C Burns; Charles L Howe
Journal:  Fluids Barriers CNS       Date:  2021-12-01

Review 4.  Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications.

Authors:  Arianna Giorgetti; Jennifer P Pascali; Paolo Fais; Guido Pelletti; Andrea Gabbin; Giorgia Franchetti; Giovanni Cecchetto; Guido Viel
Journal:  Life (Basel)       Date:  2021-05-14

5.  Estimating Mental Health Conditions of Patients with Opioid Use Disorder.

Authors:  Christopher Minnerly; Steven L Bressler; Ibrahim M Shokry; Rui Tao
Journal:  J Addict       Date:  2019-09-26

6.  Differential effects of the novel neurosteroid hypnotic (3β,5β,17β)-3-hydroxyandrostane-17-carbonitrile on electroencephalogram activity in male and female rats.

Authors:  Srdjan M Joksimovic; Dayalan Sampath; Kathiresan Krishnan; Douglas F Covey; Vesna Jevtovic-Todorovic; Yogendra H Raol; Slobodan M Todorovic
Journal:  Br J Anaesth       Date:  2021-05-08       Impact factor: 9.166

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.